Insider Buying: Kala Pharmaceuticals Inc (KALA) Major Shareholder Purchases 25,000 Shares of Stock

Kala Pharmaceuticals Inc (NASDAQ:KALA) major shareholder Orbimed Advisors Llc bought 25,000 shares of the firm’s stock in a transaction dated Thursday, February 8th. The shares were acquired at an average price of $12.93 per share, for a total transaction of $323,250.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Orbimed Advisors Llc also recently made the following trade(s):

  • On Thursday, February 1st, Orbimed Advisors Llc bought 362,240 shares of Kala Pharmaceuticals stock. The shares were acquired at an average price of $15.00 per share, for a total transaction of $5,433,600.00.
  • On Friday, January 26th, Orbimed Advisors Llc bought 22,760 shares of Kala Pharmaceuticals stock. The shares were acquired at an average price of $14.93 per share, for a total transaction of $339,806.80.
  • On Monday, January 29th, Orbimed Advisors Llc bought 72,760 shares of Kala Pharmaceuticals stock. The shares were acquired at an average price of $14.97 per share, for a total transaction of $1,089,217.20.
  • On Wednesday, January 24th, Orbimed Advisors Llc bought 64,637 shares of Kala Pharmaceuticals stock. The shares were acquired at an average price of $14.91 per share, for a total transaction of $963,737.67.
  • On Monday, January 22nd, Orbimed Advisors Llc bought 75,000 shares of Kala Pharmaceuticals stock. The shares were acquired at an average price of $14.98 per share, for a total transaction of $1,123,500.00.
  • On Friday, January 19th, Orbimed Advisors Llc bought 74,931 shares of Kala Pharmaceuticals stock. The shares were acquired at an average price of $14.95 per share, for a total transaction of $1,120,218.45.
  • On Wednesday, January 10th, Orbimed Advisors Llc bought 170,338 shares of Kala Pharmaceuticals stock. The shares were acquired at an average price of $12.83 per share, for a total transaction of $2,185,436.54.
  • On Friday, January 12th, Orbimed Advisors Llc bought 240,484 shares of Kala Pharmaceuticals stock. The shares were acquired at an average price of $13.28 per share, for a total transaction of $3,193,627.52.

Shares of Kala Pharmaceuticals Inc (NASDAQ KALA) traded up $1.14 during mid-day trading on Monday, reaching $13.61. The company’s stock had a trading volume of 370,913 shares, compared to its average volume of 517,335. The company has a quick ratio of 11.00, a current ratio of 11.00 and a debt-to-equity ratio of 0.14. The stock has a market cap of $329.73 and a price-to-earnings ratio of -7.48. Kala Pharmaceuticals Inc has a 12 month low of $11.81 and a 12 month high of $26.75.

A number of research analysts have recently issued reports on the company. Wedbush reiterated a “buy” rating and set a $46.00 target price on shares of Kala Pharmaceuticals in a research report on Thursday, November 30th. Wells Fargo & Co reiterated an “outperform” rating and set a $19.00 target price (down previously from $24.00) on shares of Kala Pharmaceuticals in a research report on Thursday, January 25th. They noted that the move was a valuation call. BidaskClub upgraded Kala Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, December 29th. JPMorgan Chase & Co. set a $35.00 price objective on Kala Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, November 19th. Finally, Zacks Investment Research lowered Kala Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. Two research analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $35.80.

A number of hedge funds have recently made changes to their positions in the business. Orbimed Advisors LLC purchased a new position in Kala Pharmaceuticals in the 3rd quarter valued at $54,251,000. BlackRock Inc. lifted its holdings in Kala Pharmaceuticals by 76.1% in the 4th quarter. BlackRock Inc. now owns 738,050 shares of the company’s stock valued at $13,646,000 after purchasing an additional 319,043 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in Kala Pharmaceuticals by 4.6% in the 4th quarter. Victory Capital Management Inc. now owns 568,635 shares of the company’s stock valued at $10,514,000 after purchasing an additional 25,110 shares in the last quarter. Caxton Corp purchased a new position in Kala Pharmaceuticals in the 3rd quarter valued at $12,430,000. Finally, Wells Fargo & Company MN lifted its holdings in Kala Pharmaceuticals by 74.5% in the 4th quarter. Wells Fargo & Company MN now owns 286,694 shares of the company’s stock valued at $5,301,000 after purchasing an additional 122,425 shares in the last quarter. Institutional investors own 63.00% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/12/insider-buying-kala-pharmaceuticals-inc-kala-major-shareholder-purchases-25000-shares-of-stock.html.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.

Insider Buying and Selling by Quarter for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply